Recent submissions
Now showing items 301-320 of 1130
-
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors.
(CELL PRESS, 2021-03-26)Prostate cancers are considered "cold" tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells. This non-inflamed phenotype is likely ... -
Clinical Application of Shear Wave Elastography for Assisting Brain Tumor Resection.
(FRONTIERS MEDIA SA, 2021-03-01)BACKGROUND: The clinical outcomes for brain tumor resection have been shown to be significantly improved with increased extent of resection. To achieve this, neurosurgeons employ different intra-operative tools to improve ... -
The role of spread through air spaces (STAS) in lung adenocarcinoma prognosis and therapeutic decision making.
(ELSEVIER IRELAND LTD, 2020-08-01)Spread through air spaces (STAS) was included as a novel pattern of invasion in lung adenocarcinoma by the World Health Organization in 2015. Since then, multiple studies have investigated the association of STAS with ... -
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.
(AMER SOC CLINICAL ONCOLOGY, 2020-08-10) -
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
(ELSEVIER SCIENCE INC, 2020-11-25)Tumor proportion score (TPS) and combined positive score ([CPS] includes immune cells), 2 methods for scoring programmed death ligand 1 (PD-L1) expression, have been used in clinical trials investigating the immune checkpoint ... -
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
(AMER ASSOC CANCER RESEARCH, 2020-10-01)PURPOSE: The prognosis for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, and only a minority of patients benefit from checkpoint immunotherapy. Talimogene laherparepvec ... -
The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma.
(ELSEVIER, 2021-02-01)OBJECTIVES: Despite wide excision and post-operative irradiation, loco-regional and/or metastatic recurrence is a significant clinical problem in salivary adenoid cystic carcinoma (SACC). Reliable biomarkers are required ... -
Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.
(BMJ PUBLISHING GROUP, 2021-03-01)BACKGROUND: Rectal cancers show a highly varied response to neoadjuvant radiotherapy/chemoradiation (RT/CRT) and the impact of the tumor immune microenvironment on this response is poorly understood. Current clinical tumor ... -
The impact of restricted length of treatment field and anthropometric factors on selection of head and neck cancer patients for treatment on the MR-Linac.
(BRITISH INST RADIOLOGY, 2020-07-01)OBJECTIVE: This study investigates the impact of a restricted craniocaudal (CC) field length of <20 cm on the selection of head and neck cancer (HNC) patients who can be treated on the MR-Linac using a single isocentre ... -
Changing paradigms in the treatment of residual/recurrent head and neck cancer: implications for dysphagia management.
(LIPPINCOTT WILLIAMS & WILKINS, 2020-06-01)PURPOSE OF REVIEW: Despite advances in head and neck cancer treatment provision, recurrence rates remain high with the added risk of successfully treated patients developing a second primary. We report on the management ... -
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
(FUTURE MEDICINE LTD, 2020-06-03)Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with ... -
The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
(AMER ASSOC CANCER RESEARCH, 2021-02-01)Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still remain to their success. Here, we ... -
International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma.
(ELSEVIER SCIENCE INC, 2021-07-01)PURPOSE: Reirradiation for locally recurrent nasopharyngeal carcinoma (NPC) is challenging because prior radiation dose delivered in the first course is often close to the tolerance limit of surrounding normal structures. ... -
TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells.
(NATURE PORTFOLIO, 2021-03-29)Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a patient-by-patient ... -
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
(ELSEVIER SCIENCE INC, 2019-11-23)BACKGROUND: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. METHODS: KEYNOTE-048 was a randomised, phase ... -
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
(FRONTIERS MEDIA SA, 2020-10-08)Cancer somatic mutations have been identified as a source of antigens that can be targeted by cancer immunotherapy. In this work, expanding on previous studies, we analyze the HLA-presentation properties of mutations that ... -
Statistical Motion Mask and Sliding Registration
(SPRINGER INTERNATIONAL PUBLISHING AG, 2018-01-01)